Table 3 Concordance between adjuvant treatments delivered to women with non-metastatic breast cancer diagnosed during 2016–2020 at the National Cancer Institute, Sri Lanka versus guidelinea recommendations
Indicator | Groups | n (%) |
|---|---|---|
Use of chemotherapy (CT) | CT indicated | 2720 (100) |
• CT should be delivered to patients with node-positive disease | CT delivered | 2464 (91) |
Use of adjuvant radiotherapy (RT) | RT indicated | 2078 (100) |
• RT should be delivered to patients after breast conserving surgery and those with 3+ positive LNs | RT delivered | 1599 (77) |
Use of adjuvant endocrine therapy (ET) | ET indicated | 3189 (100) |
• Adjuvant ET should be given to all patients with ER and/or PR positive breast positive breast cancer | ET started | 2795 (88) |
Use of adjuvant trastuzumab | Trastuzumab indicated | 947 (100) |
• Adjuvant trastuzumab should be given to all patients with HER2 positive breast cancer | Trastuzumab delivered | 559 (59) |